Jaguar Health Inc., a company listed on NASDAQ under the symbol JAGX, has shared insights into its ongoing efforts in developing plant-based medicines for gastrointestinal disorders. The presentation highlights the FDA-approved drug Mytesi, which provides symptomatic relief for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, and Canalevia®-CA1, conditionally approved for treating chemotherapy-induced diarrhea in dogs. A key focus is on Crofelemer, a non-opioid, non-addictive drug that normalizes water flow in the gastrointestinal tract, thereby reducing watery diarrhea and enhancing nutrient absorption. The company also presented Phase 2 data on Crofelemer's use in treating dehydration in cholera patients. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.